Gene therapy company Tocagen prices offering at low end of range

Tocagen Inc. , a cancer-selective gene therapy company, said Thursday that it priced its initial public offering at $10 a share, at the low end of its expected range. The company sold 8.5 million shares to raise $85 million. Tocagen had previously set an expected price range of $10 to $12 and planned to sell 7.25 million shares. The shares are expected to start trading Thursday on the Nasdaq Global Select Market under the symbol "TOCA." Tocagen has granted underwriters a 30-day option to buy an additional 1,275,000 shares of common stock.